Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Debt Ratio (2016 - 2026)

Coherus Oncology's Debt Ratio history spans 13 years, with the latest figure at 0.14 for Q1 2026.

  • On a quarterly basis, Debt Ratio fell 17.77% to 0.14 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.14, a 17.77% decrease, with the full-year FY2025 number at 0.14, up 27.84% from a year prior.
  • Debt Ratio hit 0.14 in Q1 2026 for Coherus Oncology, down from 0.14 in the prior quarter.
  • Over the last five years, Debt Ratio for CHRS hit a ceiling of 0.61 in Q1 2023 and a floor of 0.07 in Q2 2024.
  • Historically, Debt Ratio has averaged 0.27 across 5 years, with a median of 0.17 in 2025.
  • Biggest five-year swings in Debt Ratio: soared 359.28% in 2022 and later tumbled 87.06% in 2024.
  • Tracing CHRS's Debt Ratio over 5 years: stood at 0.51 in 2022, then fell by 22.29% to 0.4 in 2023, then crashed by 71.72% to 0.11 in 2024, then rose by 27.84% to 0.14 in 2025, then dropped by 2.63% to 0.14 in 2026.
  • Business Quant data shows Debt Ratio for CHRS at 0.14 in Q1 2026, 0.14 in Q4 2025, and 0.07 in Q3 2025.